| Literature DB >> 26190651 |
Xudong Fu1, Randall M Chin2, Laurent Vergnes3, Heejun Hwang1, Gang Deng4, Yanpeng Xing4, Melody Y Pai2, Sichen Li5, Lisa Ta1, Farbod Fazlollahi6, Chuo Chen7, Robert M Prins8, Michael A Teitell9, David A Nathanson1, Albert Lai5, Kym F Faull6, Meisheng Jiang1, Steven G Clarke10, Timothy F Cloughesy11, Thomas G Graeber12, Daniel Braas13, Heather R Christofk14, Michael E Jung15, Karen Reue16, Jing Huang17.
Abstract
We discovered recently that the central metabolite α-ketoglutarate (α-KG) extends the lifespan of C. elegans through inhibition of ATP synthase and TOR signaling. Here we find, unexpectedly, that (R)-2-hydroxyglutarate ((R)-2HG), an oncometabolite that interferes with various α-KG-mediated processes, similarly extends worm lifespan. (R)-2HG accumulates in human cancers carrying neomorphic mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes. We show that, like α-KG, both (R)-2HG and (S)-2HG bind and inhibit ATP synthase and inhibit mTOR signaling. These effects are mirrored in IDH1 mutant cells, suggesting a growth-suppressive function of (R)-2HG. Consistently, inhibition of ATP synthase by 2-HG or α-KG in glioblastoma cells is sufficient for growth arrest and tumor cell killing under conditions of glucose limitation, e.g., when ketone bodies (instead of glucose) are supplied for energy. These findings inform therapeutic strategies and open avenues for investigating the roles of 2-HG and metabolites in biology and disease.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26190651 PMCID: PMC4663076 DOI: 10.1016/j.cmet.2015.06.009
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287